Quick Links

Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by educational grants from Celgene Corporation and Foundation Medicine, Inc.

Advances in™ Diagnostic Guidelines for Effective Clinical Decision - Making in the Management of Hematologic Malignancies

Release Date: April 30, 2018
Expiration Date: April 30, 2019
Media: Internet - based


Activity Overview

This activity, Advances in™ Diagnostic Guidelines for Effective Clinical Decision-Making in the Management of Hematologic Malignancies, developed in PER’s established Advances in™ legacy format, is designed to highlight the rationale for the use of new diagnostic guidelines in hematologic malignancies, provide expert guidance on the interpretation of emerging strategies derived from improved guidelines, and to forecast future application of novel diagnostic and therapeutic strategies in clinical practice. You will hear expert perspectives (from a pathologist and a hematologist) and discussions of recent diagnostic updates that have the potential to advance the treatment of hematologic malignancies in the context of current treatment paradigms to improve outcomes for your patients. You will have the opportunity to enhance your skills through an interactive mix of evidence-based didactic presentations, cases, and discussion.

Acknowledgement of Commercial Support

This activity is supported by educational grants from Celgene Corporation and Foundation Medicine, Inc.

CME Activity Table of Contents

  • Module 1: Basic Concepts Underlying Molecular Testing
  • Module 2: Spotlight on Molecular Testing Use in Clinical Practice
  • Module 3: How Do You Use Molecular Testing in Your Patients?

Instructions for This Activity and Receiving Credit

  • You will need to login to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review videos/content until you finish the presentation.
  • At the end of the activity, “educational content/video files” will be available for your reference.
  • In order to receive a CME certificate, participants must complete the activity.
  • Complete the posttest and pass with a score of 70% or higher, complete the evaluation and then click on request for credit. Participants may immediately download a CME certificate upon completion of these steps.

Target Audience

This educational program is directed toward medical oncologists/hematologists and pathologists who treat patients with hematologic malignancies. Nurses, nurse practitioners, physician assistants and other healthcare professions involved in the treatment and management of hematologic malignancies are also invited to participate in the activity.

Learning Objectives

At the conclusion of this activity, you should be better prepared to:

  1. Review current testing strategies for patients with hematologic malignancies
  2. Evaluate emerging mutational analysis guidelines in the context of treatment planning for patients with hematologic malignancies
  3. Apply testing approaches to stratify risk and personalize care in the management of hematologic tumors

Faculty, Staff, and Planners' Disclosures


Ahmet Dogan, MD, PhD
Chief, Hematopathology Service,
Departments of Pathology and Laboratory Medicine
Memorial Sloan Kettering Cancer Center
New York, NY

Disclosure: Consultant: Novartis, Celgene, Seattle Genetics, Oncology Specialty Group, Roche, PeerView Institute, Pharmacyclics.

Craig H. Moskowitz, MD
Medical Oncologist
Steven A. Greenberg Chair
Clinical Director, Division of Hematologic Oncology
Memorial Sloan Kettering Cancer Center

Disclosure: Grant/Research Support: Merck, Seattle Genetics. Consultant: Celgene, Genentech, Merck, Seattle Genetics.

The staff of PER® have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical and nursing education purposes only, and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER®.

Become a Member

Forgot Password?
Calendar of Events
Filter By